Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Recorded changes
83,427 on record
Recorded policy changes, newest first| Recorded | Payer | Policy | Change |
|---|
| Aug 2, 2026 | Independence Blue Cross | Tocilizumab and Related Biosimilars for Intravenous InfusionPayerPolicy · IBX-COMMERCIAL-08-00-85 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Tisotumab vedotin-tftv (Tivdak)PayerPolicy · IBX-COMMERCIAL-08-01-83 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Tislelizumab-jsgr (Tevimbra)PayerPolicy · IBX-COMMERCIAL-08-02-23 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Tildrakizumab-asmn (Ilumya)PayerPolicy · IBX-COMMERCIAL-08-01-48 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Therapies for Spinal Muscular AtrophyPayerPolicy · IBX-COMMERCIAL-08-01-36 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Therapeutic Transcranial Magnetic Stimulation (TMS)PayerPolicy · IBX-COMMERCIAL-07-03-22 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Therapeutic Shoes and Orthopedic ShoesPayerPolicy · IBX-COMMERCIAL-05-00-11 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Therapeutic Drug Monitoring for Antidepressants, Antipsychotics, or AntiepilepticsPayerPolicy · IBX-COMMERCIAL-06-02-55 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Testing Serum Vitamin D LevelsPayerPolicy · IBX-COMMERCIAL-06-02-51 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Teprotumumab-trbw (Tepezza)PayerPolicy · IBX-COMMERCIAL-08-00-41 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Teplizumab-mzwv (Tzield)PayerPolicy · IBX-COMMERCIAL-08-01-99 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Telisotuzumab vedotin-tllv (Emrelis)PayerPolicy · IBX-COMMERCIAL-08-02-45 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Telemedicine ServicesPayerPolicy · IBX-COMMERCIAL-00-10-41 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Teclistamab-cqyv (Tecvayli)PayerPolicy · IBX-COMMERCIAL-08-01-98 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Tebentafusp-tebn (Kimmtrak)PayerPolicy · IBX-COMMERCIAL-08-01-85 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Tarlatamab-dlle (Imdelltra) for intravenous usePayerPolicy · IBX-COMMERCIAL-08-02-27 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Talquetamab-tgvs (Talvey)PayerPolicy · IBX-COMMERCIAL-08-02-16 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Tafasitamab-cxix (Monjuvi)PayerPolicy · IBX-COMMERCIAL-08-01-81 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Sutimlimab-jome (Enjaymo)PayerPolicy · IBX-COMMERCIAL-08-01-87 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Surgical Treatments of Athletic PubalgiaPayerPolicy · IBX-COMMERCIAL-11-14-26 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Surgical Treatment of Femoroacetabular Impingement (Independence Administrators)PayerPolicy · IBX-COMMERCIAL-11-14-23 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Surgical Procedures of the Eyelid and BrowPayerPolicy · IBX-COMMERCIAL-11-05-02 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Surgical Correction of StrabismusPayerPolicy · IBX-COMMERCIAL-11-05-07 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Surgical and Minimally Invasive Treatments for Urinary Outlet Obstruction due to Benign Prostatic Hyperplasia (BPH)PayerPolicy · IBX-COMMERCIAL-11-17-06 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Surgery for GynecomastiaPayerPolicy · IBX-COMMERCIAL-11-08-12 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Steroid-Eluting Sinus Stents and ImplantsPayerPolicy · IBX-COMMERCIAL-11-16-08 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Stem-Cell Therapy/Platelet-Rich Plasma for Orthopedic Applications and Platelet-Rich Plasma/Platelet-Derived Growth Factor for Wound Healing and Other Miscellaneous Non-Orthopedic ConditionsPayerPolicy · IBX-COMMERCIAL-07-07-09 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | STAT Laboratory Tests Performed in the Outpatient Hospital Setting for Health Maintenance Organization (HMO) and Point of Service (POS) ProductsPayerPolicy · IBX-COMMERCIAL-00-01-41 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Standing FramesPayerPolicy · IBX-COMMERCIAL-05-00-71 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Spinal Laminectomy (Independence Administrators)PayerPolicy · IBX-COMMERCIAL-11-14-28 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Spinal Fusion (Independence Administrators)PayerPolicy · IBX-COMMERCIAL-11-14-27 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Spinal Discectomy (Independence Administrators)PayerPolicy · IBX-COMMERCIAL-11-14-29 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Spinal Decompression with Interspinous and Interlaminar DevicesPayerPolicy · IBX-COMMERCIAL-11-14-22 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Spinal Cord Ganglion and Dorsal Root Ganglion Stimulation (Independence Administrators)PayerPolicy · IBX-COMMERCIAL-11-15-01 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Spesolimab-sbzo (Spevigo)PayerPolicy · IBX-COMMERCIAL-08-01-97 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Speech TherapyPayerPolicy · IBX-COMMERCIAL-10-06-01 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Speech and Non-Speech Generating DevicesPayerPolicy · IBX-COMMERCIAL-05-00-32 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Solid Organ Transplantation and Procurement Cost of Organs and TissuesPayerPolicy · IBX-COMMERCIAL-11-00-09 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Sleep Disorder Testing and Positive Airway Pressure Therapy Services and SuppliesPayerPolicy · IBX-COMMERCIAL-07-03-05AB-BB7C0BDB6F | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Skilled Nursing Facility (SNF): Skilled and Subacute Levels of CarePayerPolicy · IBX-COMMERCIAL-02-03-00 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Site of Care for Elective Procedures [Hospital Outpatient Setting to Ambulatory Surgical Center (ASC)]PayerPolicy · IBX-COMMERCIAL-12-06-00 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Short-term Interstitial Continuous Glucose Monitoring Systems (CGMS)PayerPolicy · IBX-COMMERCIAL-05-00-24 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Services Paid Above Capitation for Health Maintenance Organization (HMO) and Health Maintenance Organization Point-of-Service (HMO-POS) Primary Care ProvidersPayerPolicy · IBX-COMMERCIAL-00-10-01AN-7FAFE94057 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Serodiagnosis of Inflammatory Bowel Disease (IBD) and the Prometheus IBD sgi Diagnostic TestPayerPolicy · IBX-COMMERCIAL-06-02-17 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Sentinel Lymph Node Biopsy and MappingPayerPolicy · IBX-COMMERCIAL-11-07-02 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Self-Administered Drugs and BiologicsPayerPolicy · IBX-COMMERCIAL-08-00-78AX-8845E90EE6 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Selective Photothermolysis Using Pulsed-Dye Lasers (PDL)PayerPolicy · IBX-COMMERCIAL-11-08-04 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Secukinumab (Cosentyx) for Intravenous UsePayerPolicy · IBX-COMMERCIAL-08-02-28 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Sebelipase alfa (Kanuma)PayerPolicy · IBX-COMMERCIAL-08-01-28 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Seat Lift MechanismsPayerPolicy · IBX-COMMERCIAL-05-00-43 | New policy |
|---|